Condition: Primary Plasma Cell Leukemia · Sponsor: Hellenic Society of Hematology
The primary objective of this study is to evaluate the efficacy of the alternating D-PAD/D-CVD induction regimen followed by D-CVD consolidation regimen and maintenance with daratumumab monotherapy, in terms of PFS, in the first-line setting of pPCL.
This description comes directly from the study's public registry record.
Eirini Katodritou, Dr · +302313301173 · eirinikatodritou@gmail.com
Marina Stogianni · 0030 2107211806 · info@eae.gr
Always discuss trial participation with your own doctor first.
| 1st Propaedeutic Department, "Laiko" General Hospital of Athens | Athens, Attica, Greece | Recruiting |
| Hematology Clinic, General Hospital of Athens "Evanggelismos" | Athens, Attica, Greece | Recruiting |
| Hematology Department "Alexandra" General Hospital of Athens | Athens, Attica, Greece | Recruiting |
| Hematology Department, University General Hospital of Alexandroupolis | Alexandroupoli, Evros, Greece | Recruiting |
| Hematology Department, Regional General Hospital for Cancer Treatment "Metaxa" of Piraeus | Piraeus, Greece | Recruiting |
| Hematology Department, General Hospital of Thessaloniki "Papanikolaou" | Thessaloniki, Greece | Recruiting |
| Hematology Department, Theageneion Cancer Hospital | Thessaloniki, Greece | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06636552